NCT03912883Active, not recruiting
Prognostic Factors in Prostate Cancer for Patients Treated by Watchful Waiting
Source: ClinicalTrials.gov · Last updated 18 Nov 2025
Brief summary (registry, in English)
The Trans-Atlantic Prostate Group (TAPG) was established to examine the hypothesis that through a detailed retrospective analysis of outcome in a group of men with clinically localised prostate cancer at diagnosis, variables such as biological, pathological and clinical markers, could be identified that might accurately predict the prognosis of clinically localised prostate cancer.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 3350 (estimated)
- First submitted
- 14 Feb 2019
- Start date
- 12 Oct 1999
- Primary completion date
- 1 Jan 2030
- Lead sponsor
- Queen Mary University of London
- Diseases
- Prostate cancer
- NCT number
- NCT03912883
What you commit to
- Study type: Observational
- Planned participants: 3350
- From 12 Oct 1999 to the primary completion date, 1 Jan 2030
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with evidence of metastatic disease
Lab values
- Patients who have not had a baseline serum PSA level measured before starting any treatment
Age
- Patients older than 76 years at the time of diagnosis
Other
- Patients who do not have the initial diagnosis biopsy sample for review
Who the study is looking for
- Patients must be aged less than 76 years at the time of diagnosis
- Patients must have had a baseline serum PSA level measured before starting any treatment and within six months of diagnosis
- Patients must have been diagnosed between 1990 and 2006 with a clinically localized (clinical stage T1-T3, N0 or NX, MO or MX) prostate cancer, in the judgment of the treating physician
- The initial diagnostic biopsy sample must be available for review. Patients should have (but are not required to have) tissue blocks available for review.
- There must be no evidence of metastatic disease
- While data collection will include review of the reports of any imaging studies of the prostate, bones, or soft tissues, these studies are not essential
- Each patient should have had an adequate medical evaluation to document the status of disease for the first five years after diagnosis. Follow-up should include an annual PSA and digital rectal examination. Records will be reviewed to seek all information about medical evaluation after the time of diagnosis.
Age in the registry: 18 years to 76 years · Sex: Male · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.